Biotechnology firm Alterity Therapeutics Inc.
(NASDAQ:ATHE) on Wednesday announced a major intellectual property milestone after receiving a new composition-of-matter patent from the United States Patent and Trademark Office for its lead clinical asset, ATH434.
The decision fortifies the company’s long-term commercial potential as it prepares to initiate Phase 3 trial activities in Multiple System Atrophy by year-end 2026.
Alterity Therapeutics Intellectual Property Portfolio Expansion The USPTO granted the patent entitled "Crystalline Form, and Process for its Production," which covers the composition of matter of a crystalline form of ATH434 mesylate alongside methods for treating neurological conditions using it.
Protecting this novel solid-state crystalline form and treatment methods provides another vital layer of commercial protection for treating Multiple System Atrophy and additional neurodegenerative disorders.
